Trial Profile
A Prospective, Open-Label, Non-Randomized, Clinical Trial to Determine if Natalizumab (Tysabri) Improves Ambulatory Measures in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients. 'TIMER' Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Mar 2017
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms TIMER
- Sponsors Biogen Idec
- 26 Jul 2012 Planned end date changed from 1 May 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Feb 2012 Planned end date changed from 1 Aug 2011 to 1 May 2012 as reported by ClinicalTrials.gov.